Four months into Trump’s Presidency, there hasn’t been much traction in lowering prescription drug prices. The issue was one of Trump’s major campaign themes before he took office, but the Russia investigation, immigration, tax reform, and infrastructure have all been more pressing issues for the administration. Health and Human Services Secretary Tom Price told senators last week that lowering prescription drug prices is still a major priority for the President. One proposal Trump advocates have floated is enabling generic drugs to hit the market faster. This would come through changes to FDA regulations. The FDA is already seeking to eliminate the year long backlog of over 2,500 generic drug applications. Generic drugs hitting the market faster would enhance competition, and FDA and regulatory law firms are surely working on proposals to be considered by the Trump Administration.